Integra LifeSciences Holdings Corporation (IART) Holdings Lifted by Sei Investments Co.

Sei Investments Co. grew its position in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 29.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 177,525 shares of the life sciences company’s stock after purchasing an additional 40,369 shares during the period. Sei Investments Co. owned approximately 0.23% of Integra LifeSciences Holdings Corporation worth $8,961,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IART. Acrospire Investment Management LLC grew its position in Integra LifeSciences Holdings Corporation by 280.0% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock worth $104,000 after purchasing an additional 1,400 shares during the last quarter. Riverhead Capital Management LLC grew its position in Integra LifeSciences Holdings Corporation by 49.9% in the 2nd quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock worth $131,000 after purchasing an additional 799 shares during the last quarter. LS Investment Advisors LLC grew its position in Integra LifeSciences Holdings Corporation by 4.6% in the 2nd quarter. LS Investment Advisors LLC now owns 2,523 shares of the life sciences company’s stock worth $138,000 after purchasing an additional 111 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Integra LifeSciences Holdings Corporation by 8.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock worth $150,000 after purchasing an additional 218 shares during the last quarter. Finally, Whittier Trust Co. bought a new position in Integra LifeSciences Holdings Corporation in the 3rd quarter worth about $169,000. Hedge funds and other institutional investors own 83.99% of the company’s stock.

In other Integra LifeSciences Holdings Corporation news, Director Barbara B. Hill bought 10,768 shares of Integra LifeSciences Holdings Corporation stock in a transaction that occurred on Tuesday, October 31st. The stock was purchased at an average cost of $46.66 per share, for a total transaction of $502,434.88. Following the completion of the acquisition, the director now owns 55,540 shares of the company’s stock, valued at approximately $2,591,496.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Richard D. Gorelick sold 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total transaction of $70,785.00. Following the sale, the vice president now owns 21,665 shares of the company’s stock, valued at $1,022,371.35. The disclosure for this sale can be found here. Company insiders own 21.50% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/21/integra-lifesciences-holdings-corporation-iart-holdings-lifted-by-sei-investments-co.html.

Several research analysts have commented on the stock. Zacks Investment Research upgraded shares of Integra LifeSciences Holdings Corporation from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a research report on Tuesday, October 10th. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a report on Wednesday, July 26th. Raymond James Financial, Inc. increased their price objective on shares of Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the company an “outperform” rating in a report on Thursday, July 27th. UBS AG reiterated a “buy” rating and issued a $57.00 price objective on shares of Integra LifeSciences Holdings Corporation in a report on Tuesday, October 31st. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $56.00 price objective on shares of Integra LifeSciences Holdings Corporation in a report on Sunday, October 29th. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $53.82.

Shares of Integra LifeSciences Holdings Corporation (IART) opened at $47.40 on Tuesday. The firm has a market cap of $3,732.39, a P/E ratio of 26.28, a P/E/G ratio of 2.07 and a beta of 0.64. Integra LifeSciences Holdings Corporation has a 1-year low of $37.71 and a 1-year high of $56.42. The company has a current ratio of 4.49, a quick ratio of 3.39 and a debt-to-equity ratio of 1.26.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last issued its earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.47 by ($0.02). The business had revenue of $278.83 million for the quarter, compared to the consensus estimate of $286.00 million. Integra LifeSciences Holdings Corporation had a return on equity of 16.35% and a net margin of 4.52%. The company’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.93 earnings per share. equities research analysts predict that Integra LifeSciences Holdings Corporation will post 1.87 EPS for the current fiscal year.

Integra LifeSciences Holdings Corporation Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply